181871-69-2

Basic information

• Product Name: Benzoic acid, 3-chloro-4-Methyl-5-nitro-
• Synonyms: Benzoic acid, 3-chloro-4-Methyl-5-nitro-;3-chloro-4-methyl-5-nitrobenzoic acid
• CAS NO: 181871-69-2
• Molecular Formula: C₈H₆ClNO₄
• Molecular Weight: 215.59054
• Mol File: 181871-69-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 3-chloro-4-Methyl-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-chloro-4-Methyl-5-nitro-(181871-69-2)
• EPA Substance Registry System: Benzoic acid, 3-chloro-4-Methyl-5-nitro-(181871-69-2)

Safety Data

• Hazardous Substances Data: 181871-69-2(Hazardous Substances Data)

Upstream product

• 10202-92-3 3-methyl-2,4-dinitroaniline 
• 54591-62-7 3-amino-4-methyl-5-nitrobenzoic acid 
• 16533-71-4 3,5-dinitro-p-toluic acid 
• 5162-82-3 3-chloro-4-methylbenzoic acid 

Downstream Products

• 1092307-34-0 3-amino-5-chloro-4-methyl-benzoic acid 
• 1135253-13-2 3-chloro-5-hydroxy-4-methyl-benzoic acid 
• 1170078-37-1 2-chloro-6-nitroterephthalic acid 
• 1002110-73-7 3-Chloro-N-(3-chlorobenzyl)-4-methyl-5-nitrobenzamide 
• 39652-34-1 3,5-dichloro-4-methylbenzoic acid 

Relevant articles and documents

2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS

The invention relates to substituted indazoles and methods for production thereof and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, especially of cardiovascular diseases, preferably of thromboemboli

2-IMIDAZOLINE, 2-OXAZOLINE, 2-THIAZOLINE, AND 4-IMIDAZOLE DERIVATIVES OF METHYLPHENYL, METHOXYPHENYL, AND AMINOPHENYL ALKYLSULFONAMIDES AND UREAS AND THEIR USE

The present invention concerns novel compounds represented by the Formula: STR1 wherein: A is R 1 q (R 3 R 60 N). sub.m (Z)(NR 2) n ; m and q are each 0 or 1, with the proviso that when q is 1, m is 0 and when q is 0, m is 1; Z is C=O or SO 2 ; n is 1 with the proviso that, when Z is C=O, m is 1; X is--NH--,--CH 2--, or--OCH 2--; Y is 2-imidazoline, 2-oxazoline, 2-thiazoline, or 4-imidazole; R 1 is H, lower alkyl, or phenyl, with the proviso that, when R 1 is H, m is 1; R 2, R 3, R 60 are each independently H, lower alkyl, or phenyl; R 4, R 5, R. sup.6, and R 7 are each independently hydrogen, lower alkyl,--CF. sub.3, lower alkoxy, halogen, phenyl, lower alkeny, hydroxyl, lower alkylsulfonamido, or lower cycloalkyl, wherein R. sup.2 and R 7 optionally may be taken together to form alkylene or alkenylene of 2 to 3 atoms in an unsubstituted or optionally substituted 5-or 6-membered ring, wherein the optional substituents on the ring are halo, lower alkyl, or--CN, with the proviso that, when R 7 is hydroxyl or lower alkylsulfonamido, then X is not--NH--when Y is 2-imidazoline. The compounds include pharmaceutically acceptable salts of the above. In the above formula A may be, for example, (R 1 SO 2 NR 2--), (R. sup.3 R 60 NSO 2 NR 2--), or (R 3 R 60 NCONR 2--). The invention also includes the use of the above compounds, and compositions containing them, as alpha 1A/1L agonists in the treatment of various disease states such as urinary incontinence, nasal congestion, priapism, depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and cognition, and eating disorders such as obesity, bulimia, and anorexia.